Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
gptkb:Hervé_Hoppenot
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focusArea |
oncology
inflammation autoimmunity |
| gptkbp:foundedYear |
1991
|
| gptkbp:fullName |
gptkb:Incyte_Corporation
|
| gptkbp:headquartersLocation |
gptkb:Wilmington,_Delaware,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
INCY
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:ISIN |
US45337C1027
|
| gptkbp:marketCap |
over $15 billion (2024)
|
| gptkbp:notableProduct |
gptkb:Jakafi
gptkb:Opzelura gptkb:Pemazyre |
| gptkbp:numberOfEmployees |
2000+
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:INCY
|
| gptkbp:website |
https://www.incyte.com/
|
| gptkbp:bfsParent |
gptkb:Incyte
|
| gptkbp:bfsLayer |
6
|